Fortis Healthcare Limited has informed the Exchange regarding Change in Auditors of the company.
FORTIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fortis Healthcare's Board met on August 6, 2025 and approved unaudited standalone and consolidated financial results for Q1 FY26 (quarter ended June 30, 2025). Standalone revenue from operations grew sharply to ₹43,303 lacs from ₹33,340 lacs in the same quarter last year (~30% growth), while net profit nearly doubled to ₹5,188 lacs from ₹2,683 lacs. EPS rose to ₹0.69 from ₹0.36, and EBITDA stood at ₹12,812 lacs. The Board also appointed M/s. B S R & Co. LLP as Tax Auditors for FY 2024-25; this is the same firm that continues as statutory auditor. The filing also updates on ongoing matters including the SFIO investigation, RHT Health Trust transactions under Supreme Court scrutiny, and the successful acquisition of the 'Fortis' brand at Delhi High Court auction for ₹20,000 lacs.
Strong Q1 results with significant revenue and profit growth should be viewed positively by shareholders. The appointment of the tax auditor is routine and not a change in the statutory auditor. Ongoing legacy legal matters (SFIO, RHT) remain pending but are largely historical and already provisioned.